Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Reactions
Skin
Erythema (1.9%)
Fungal dermatitis (1.1%)
Pruritus (1.3%)
Rash (sic) (1.9%)
Xerosis (1.7%)
Mucosal
Xerostomia (40%)
(2007): Yang Y+, Chin Med J (Engl) 120(5), 370
(2006): Anderson RU+, Int Urogynecol J Pelvic Floor Dysfunct
17(5), 502
(2006): Nitti VW+, BJU Int 97(6), 1262 (9%)
(2006): Roehrborn CG+, BJU Int 97(5), 1003 (16%)
(2005): Armstrong RB+, Int Urol Nephrol 37(2), 247 (21%)
(2004): Chapple CR+, BJU Int 93(3), 303 (18%)
(2004): Ethans KD+, JSpinalCordMed27(3), 214
(2003): Homma Y+, BJU Int 92(7), 741 (33.5%)
(2002): Zinner NR+, JAmGeriatrSoc50(5), 799
(2001): Crandall C, J Womens Health Gend Based Med 10(8), 735
(2001): Harvey MA+, Am J Obstet Gynecol 185(1), 56
(2001): Jacquetin B+, Eur J Obstet Gynecol Reprod Biol 98(1), 97
(2001): Layton D+, Drug Saf 24(9), 703
(2001): Malone-Lee J+, JUrol165(5), 1452 (37%)
(2001): Olsson B+, Clin Pharmacokinet 40(3), 227
(2001): Van Kerrebroeck+, Urology 57(3), 414
(1999): Drutz HP+, Int Urogynecol J Pelvic Floor Dysfunct 10, 283
(1999): Millard R+, JUrol161, 1551
(1999): Ruscin JM+, Ann Pharmacother 33, 1073
(1997): Appell RA, Urology 50, 90
(1997): Jonas U+, World J Urol 15, 144 (9%)
Other
Abdominal pain
(2001): Layton D+, Drug Saf 24(9), 703
Upper respiratory infection (5.9%)
TOPIRAMATE
Trade name: Topamax (Ortho-McNeil)
Indications: Partial onset seizures
Category: Anticonvulsant; Mood stabilizer
Half-life: 21 hours
Reactions
Skin
Acne (>1%)
Basal cell carcinoma (